Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
about
Anti-angiogenic agents in metastatic colorectal cancerPretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis modelNeoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysisEarly Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort studyThe safety of monoclonal antibodies for treatment of colorectal cancer.Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer.CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients.A prognostic nomogram for colorectal cancer liver metastases after percutaneous thermal ablation.Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases.Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
P2860
Q26801911-ED245BEB-CB0C-40DB-A949-A3558A19B9AAQ35777174-631E2705-CDFF-4F41-B15E-EAD6DC67E2E1Q35826810-09F65A0B-BC33-45BB-9C6F-0DA50E84818EQ35840971-19E6E6B2-A8C4-41FB-9054-6FCFC784D56FQ37226458-FF896763-2FCE-49BD-8026-B6606C719A6CQ38776999-C8B508C3-6983-4BAF-AB8E-81FE3C681F4CQ40616446-1CEA6AE4-B9C9-4625-BC52-A5C00E02D880Q41195740-611FCE8D-FF61-45E6-A159-CCE56E9DC90CQ46228932-AB875496-7BE0-4EBE-ADDA-64B9B29702A5Q47292036-7D081658-B826-42E6-AC87-BBC0DE6EF399Q49073965-BC918C91-5C55-4E40-A000-DA4C80D01CEEQ50211002-5C207329-5A78-4AC2-A55C-71FE8DC3B7E7Q51014362-233FCC46-74A4-4AAE-8224-D282225C0665Q53480881-A3509619-815F-4339-A01F-A7E97CBB3C34
P2860
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Neoadjuvant FOLFIRI+bevacizuma ...... ectal cancer: a phase 2 trial.
@en
type
label
Neoadjuvant FOLFIRI+bevacizuma ...... ectal cancer: a phase 2 trial.
@en
prefLabel
Neoadjuvant FOLFIRI+bevacizuma ...... ectal cancer: a phase 2 trial.
@en
P2093
P2860
P50
P921
P356
P1476
Neoadjuvant FOLFIRI+bevacizuma ...... rectal cancer: a phase 2 trial
@en
P2093
A Ottaiano
E de Lutio di Castelguidone
M C Piccirillo
P Giordano
P2860
P2888
P304
P356
10.1038/BJC.2013.140
P407
P577
2013-04-04T00:00:00Z